Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Current Trends in Prostate Imaging and Its Management
share announcement

Current Trends in Prostate Imaging and Its Management

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 7906

Special Issue Editors

Prof. Dr. Vikram Singh Dogra

E-Mail Website
Guest Editor
Department of Imaging Sciences, University of Rochester, Rochester, NY, USA
Interests: GU radiology; prostate cancer; photoacoustic imaging; ultrasound; CT and MRI
Dr. Sadhna Verma

E-Mail Website
Guest Editor
Department of Radiology, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
Interests: prostate cancer; GU radiology; MR; CT; ultrasound; PET; spectroscopy

Special Issue Information

Dear Colleagues,

This issue will present the latest developments about the prostate from a clinical perspective and new approaches in diagnosis and management. The topics will range from the latest guidelines in prostate cancer management to learning the fundamental principles and clinical applications of the diagnostic and risk assessment imaging test of choice for prostate cancer: multiparametric prostate MRI. This Special issue, in addition, will provide:

  • An essential and practical guide to performing and interpreting state-of-the-art prostate MRI utilizing the latest guidelines in the field.
  • A review of relevant prostate anatomy and pathology as applicable to current imaging and interpretation standards, including the state-of-the-art PIRADS v2.1.
  • A review of the new trends in PET imaging, including PSMA PET imaging.
  • MRI- Ultrasound fused approach to prostate Biopsy- How it is done.
  • The latest update in the surgical management of Prostate cancer, including new developments in Robotic Surgery.
  • Role of Image guided Focal therapy using HIFU, Cryotherapy, IRE and other ablation techniques in treating prostate cancer.
  • Current trends in medical oncology in the treatment of prostate cancer.
  • And will also discuss current updates in the use of radiation therapy for prostate cancer treatment.

Prof. Dr. Vikram Singh Dogra
Dr. Sadhna Verma
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (4 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

10 pages, 3840 KiB  
Article
Thin-Slice Prostate MRI Enabled by Deep Learning Image Reconstruction
by Sebastian Gassenmaier, Verena Warm, Dominik Nickel, Elisabeth Weiland, Judith Herrmann, Haidara Almansour, Daniel Wessling and Saif Afat
Cancers 2023, 15(3), 578; https://doi.org/10.3390/cancers15030578 - 18 Jan 2023
Cited by 11 | Viewed by 2019
Abstract
Objectives: Thin-slice prostate MRI might be beneficial for prostate cancer diagnostics. However, prolongation of acquisition time is a major drawback of thin-slice imaging. Therefore, the purpose of this study was to investigate the impact of a thin-slice deep learning accelerated T2-weighted (w) TSE [...] Read more.
Objectives: Thin-slice prostate MRI might be beneficial for prostate cancer diagnostics. However, prolongation of acquisition time is a major drawback of thin-slice imaging. Therefore, the purpose of this study was to investigate the impact of a thin-slice deep learning accelerated T2-weighted (w) TSE imaging sequence (T2DLR) of the prostate as compared to conventional T2w TSE imaging (T2S). Materials and Methods: Thirty patients were included in this prospective study at one university center after obtaining written informed consent. T2S (3 mm slice thickness) was acquired first in three orthogonal planes followed by thin-slice T2DLR (2 mm slice thickness) in axial plane. Acquisition time of axial conventional T2S was 4:12 min compared to 4:37 min for T2DLR. Imaging datasets were evaluated by two radiologists using a Likert-scale ranging from 1–4, with 4 being the best regarding the following parameters: sharpness, lesion detectability, artifacts, overall image quality, and diagnostic confidence. Furthermore, preference of T2S versus T2DLR was evaluated. Results: The mean patient age was 68 ± 8 years. Sharpness of images and lesion detectability were rated better in T2DLR with a median of 4 versus a median of 3 in T2S (p < 0.001 for both readers). Image noise was evaluated to be significantly worse in T2DLR as compared to T2S (p < 0.001 and p = 0.021, respectively). Overall image quality was also evaluated to be superior in T2DLR versus T2S with a median of 4 versus 3 (p < 0.001 for both readers). Both readers chose T2DLR in 29 cases as their preference. Conclusions: Thin-slice T2DLR of the prostate provides a significant improvement of image quality without significant prolongation of acquisition time. Full article
(This article belongs to the Special Issue Current Trends in Prostate Imaging and Its Management)
►▼ Show Figures

Figure 1

Review

Jump to: Research

14 pages, 3265 KiB  
Review
MRI–Ultrasound Fused Approach for Prostate Biopsy—How It Is Performed
by Jacob Lang, Timothy Dale McClure and Daniel J. A. Margolis
Cancers 2024, 16(7), 1424; https://doi.org/10.3390/cancers16071424 - 7 Apr 2024
Viewed by 665
Abstract
The use of MRI–ultrasound image fusion targeted biopsy of the prostate in the face of an elevated serum PSA is now recommended by multiple societies, and results in improved detection of clinically significant cancer and, potentially, decreased detection of indolent disease. This combines [...] Read more.
The use of MRI–ultrasound image fusion targeted biopsy of the prostate in the face of an elevated serum PSA is now recommended by multiple societies, and results in improved detection of clinically significant cancer and, potentially, decreased detection of indolent disease. This combines the excellent sensitivity of MRI for clinically significant prostate cancer and the real-time biopsy guidance and confirmation of ultrasound. Both transperineal and transrectal approaches can be implemented using cognitive fusion, mechanical fusion with an articulated arm and electromagnetic registration, or pure software registration. The performance has been shown comparable to in-bore MRI biopsy performance. However, a number of factors influence the performance of this technique, including the quality and interpretation of the MRI, the approach used for biopsy, and experience of the practitioner, with most studies showing comparable performance of MRI–ultrasound fusion to in-bore targeted biopsy. Future improvements including artificial intelligence promise to refine the performance of all approaches. Full article
(This article belongs to the Special Issue Current Trends in Prostate Imaging and Its Management)
►▼ Show Figures

Figure 1

19 pages, 346 KiB  
Review
Current Trends in Chemotherapy in the Treatment of Metastatic Prostate Cancer
by Janice Zhao, Brendan J. Guercio and Deepak Sahasrabudhe
Cancers 2023, 15(15), 3969; https://doi.org/10.3390/cancers15153969 - 4 Aug 2023
Cited by 5 | Viewed by 1666
Abstract
Prostate cancer is the second most common cancer among men. Despite advances in diagnosis and management, prostate cancer led to more than 300,000 deaths globally in 2020. Chemotherapy is a cornerstone of therapy for advanced prostate cancer and can prolong survival of patients [...] Read more.
Prostate cancer is the second most common cancer among men. Despite advances in diagnosis and management, prostate cancer led to more than 300,000 deaths globally in 2020. Chemotherapy is a cornerstone of therapy for advanced prostate cancer and can prolong survival of patients with both castration-sensitive and castration-resistant disease. Herein, we present a comprehensive review of the data supporting implementation of chemotherapy in the modern treatment of advanced prostate cancer, with special attention to the use of chemotherapy for aggressive variant prostate cancer (e.g., neuroendocrine prostate cancer) and the combination of chemotherapy with androgen signaling inhibitors. As the field of prostate cancer research continues to rapidly evolve yielding novel agents and treatment modalities, chemotherapy continues to play an essential role in prolonging the survival of patients with advanced and metastatic prostate cancer. Full article
(This article belongs to the Special Issue Current Trends in Prostate Imaging and Its Management)
21 pages, 8111 KiB  
Review
Prostate Cancer—PET Imaging Update
by Sankarsh Jetty, James Ryan Loftus, Abhinav Patel, Akshya Gupta, Savita Puri and Vikram Dogra
Cancers 2023, 15(3), 796; https://doi.org/10.3390/cancers15030796 - 28 Jan 2023
Cited by 2 | Viewed by 3097
Abstract
Prostate cancer is the most common non-dermatologic cancer in men, and one of the leading causes of cancer-related mortality. The incidence of prostate cancer increases precipitously after the age of 65 and demonstrates variable aggressiveness, depending on its grade and stage at diagnosis. [...] Read more.
Prostate cancer is the most common non-dermatologic cancer in men, and one of the leading causes of cancer-related mortality. The incidence of prostate cancer increases precipitously after the age of 65 and demonstrates variable aggressiveness, depending on its grade and stage at diagnosis. Despite recent advancements in prostate cancer treatment, recurrence is seen in 25% of patients. Advancements in prostate cancer Positron Emission Tomography (PET) molecular imaging and recent United States Food and Drug Administration (FDA) approvals have led to several new options for evaluating prostate cancer. This manuscript will review the commonly used molecular imaging agents, with an emphasis on Fluorine-18 fluciclovine (Axumin) and PSMA-ligand agents, including their protocols, imaging interpretation, and pitfalls. Full article
(This article belongs to the Special Issue Current Trends in Prostate Imaging and Its Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-4
Back to TopTop